This is a summary of the European public assessment report (EPAR) for Sycrest. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sycrest.
- What is Sycrest?
Sycrest is a medicine that contains the active substance asenapine. It is available as white, round sublingual tablets (5 and 10 mg). Sublingual tablets are tablets that are placed under the tongue, where they dissolve.
- What is Sycrest used for?
Sycrest is used to treat moderate to severe manic episodes (extremely high mood) in adults (aged 18 years or over) with bipolar disorder, a mental illness in which patients have periods of abnormally high mood alternating with periods of normal or depressed mood.
The medicine can only be obtained with a prescription.
- How is Sycrest used?
The recommended dose of Sycrest when used on its own is 10 mg twice a day, one dose in the morning and one in the evening. This dose can be reduced to 5 mg twice a day depending on how the patient responds. If Sycrest is used in combination with another medicine to treat manic episodes, the dose should be 5 mg twice a day, which can be increased if necessary to 10 mg twice a day.
Sycrest tablets should not be chewed or swallowed. When taken in combination with other medicines, Sycrest should be taken last. The patient should avoid eating or drinking for 10 minutes after taking the medicine.
- How does Sycrest work?
The active substance in Sycrest, asenapine, is an antipsychotic medicine. It is known as an ‘atypical’ antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Its exact mechanism of action is unknown, but it attaches to several different receptors on the surface of nerve cells in the brain. This disrupts signals transmitted between brain cells by ‘neurotransmitters’, chemicals that allow nerve cells to communicate with each other. It is thought that Sycrest works by blocking receptors for the neurotransmitters 5‑hydroxytrypamine (also called serotonin) and dopamine. Since these neurotransmitters are involved in bipolar disorder, Sycrest helps to normalise the activity of the brain, reducing the symptoms of the disease.
- How has Sycrest been studied?
The effects of Sycrest were first tested in experimental models before being studied in humans.
Four main studies looked at the use of Sycrest for manic episodes in bipolar disorder. In two of these studies, a total of 977 adult patients were given Sycrest, olanzapine (another antipsychotic medicine) or placebo over three weeks. The other two studies lasted longer: one compared Sycrest with olanzapine over nine weeks in patients who had come from the short-term studies, and the other was a 12-week ‘add-on’ study, in which 326 patients who were already being treated with another medicine (lithium or valproic acid) were also given either Sycrest or placebo. The main measure of effectiveness was the change in the patients’ ‘young-mania-rating-scale’ (Y-MRS) score after three weeks. The Y-MRS rates the severity of symptoms of manic episodes on a scale from 0 to 60.
Sycrest was also studied in patients with schizophrenia. The studies included short- and long-term studies in patients receiving Sycrest, other medicines for schizophrenia (olanzapine, risperidone or haloperidol) or placebo.
- What benefit has Sycrest shown during the studies?
Sycrest was effective at treating manic episodes in patients with bipolar disorder. In the first short-term study, the reductions in Y-MRS score after three weeks were 11.5 and 14.6 points for Sycrest and olanzapine, respectively, compared with 7.8 points for placebo. The reductions for the second short-term study were 10.8 and 12.6 points for Sycrest and olanzapine, respectively, and 5.5 for placebo.
In the first long-term study, a reduction in Y-MRS score of 12.9 was seen in patients taking Sycrest compared with 16.2 in patients taking olanzapine. In the second long-term study, the reductions in Y‑MRS score were 10.3 and 7.9 for Sycrest and placebo, respectively, after three weeks and 12.7 and 9.3 after 12 weeks.
The studies on schizophrenia were not considered to have shown sufficient evidence of the effectiveness in treating this disease.
- What is the risk associated with Sycrest?
The most common side effects with Sycrest (seen in more than 1 patient in 10) are anxiety and somnolence (sleepiness). For the full list of all side effects reported with Sycrest, see the package leaflet.
Sycrest should not be used in people who may be hypersensitive (allergic) to asenapine or any of the other ingredients.
- Why has Sycrest been approved?
The CHMP decided that Sycrest’s benefits are greater than its risks and recommended that it be given marketing authorisation for the treatment of moderate to severe manic episodes in patients with bipolar disorder.
The CHMP, however, did not recommend that the medicine be authorised to treat schizophrenia because of the lack of effectiveness shown in this illness.
- Other information about Sycrest
The European Commission granted a marketing authorisation valid throughout the European Union for Sycrest to N.V. Organon on 1 September 2010. The marketing authorisation is valid for five years, after which it can be renewed.
For more information about treatment with Sycrest, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This EPAR was last updated on 28/01/2013 .
17/10/2012 Sycrest -EMEA/H/C/001177 -II/0011
|Name||Language||First published||Last updated|
|Sycrest : EPAR - Product Information||BG = bălgarski||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||ES = español||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||CS = čeština||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||DA = dansk||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||DE = Deutsch||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||ET = eesti keel||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||EL = elliniká||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||EN = English||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||FR = français||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||IT = italiano||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||LV = latviešu valoda||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||LT = lietuvių kalba||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||HU = magyar||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||MT = Malti||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||NL = Nederlands||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||PL = polski||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||PT = português||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||RO = română||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||SK = slovenčina||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||SL = slovenščina||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||FI = suomi||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||SV = svenska||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||IS = Islenska||22/09/2010||28/01/2013|
|Sycrest : EPAR - Product Information||NO = Norsk||22/09/2010||28/01/2013|
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Changes since initial authorisation of medicine
|Name||Language||First published||Last updated|
|Sycrest : EPAR - Procedural steps taken and scientific information after authorisation||(English only)||14/03/2011||28/01/2013|
Initial marketing-authorisation documents
This medicine is approved for use in the European Union